Behbahani Ali 4

What Happened

• Ali Behbahani, a director of Black Diamond Therapeutics, was granted a derivative award covering 40,000 shares on June 26, 2026. The Form 4 reports the transaction price as $0.00 (derivative award), so no cash changed hands at grant and no immediate sale or exercise occurred.

Key Details

• Transaction date: June 26, 2026; Form 4 filed June 29, 2026 (three days later).
• Transaction type: Grant / award (derivative).
• Shares awarded: 40,000; reported transaction price: $0.00; reported value: $0.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The option vests in full on the earlier of (i) June 26, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service.
• No 10b5-1 plan, tax-withholding, cashless exercise, or late-filing flag is indicated in the summary information provided.

Context

• This is a compensation-related option grant (a potential future economic interest) rather than an open-market purchase or sale. It does not represent an immediate buy or sell signal; the award vests in the future and would only have economic impact if and when exercised or sold after vesting.